^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YT-19

    i
    Other names: CD19-STAR-T cells, CD19-Synthetic T Cell Antigen Receptor Therapy, YT-19
    Company:
    BriSTAR Immunotech
    Drug class:
    CD19 inhibitor
    Related drugs:
    4years
    [VIRTUAL] A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL) (ASH 2020)
    Here, we report pre-clinical and first-in-human phase I trial results of CD19 STAR-T cell therapy for CD19+ R/R B-ALL...Patients received a conditioning regimen of IV fludarabine (25mg/m2/d) and cyclophosphamide (250mg/m2/d) for 3 days followed by a single STAR T-cell infusion...A high CR could be achieved on day 14 with low toxicity. Longer-term observation of these patients and studies of larger patient cohorts are warranted.
    Clinical
    |
    CD19 (CD19 Molecule)
    |
    fludarabine IV • YT-19 • SENL-B19